LSA
TVRD

Leonteq Securities AG’s Tvardi Therapeutics TVRD Stock Holding History

Leonteq Securities AG’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23 Hold
12
– – ﹤0.01% 1263
2026
Q1 		$38 Hold
12
– – ﹤0.01% 1266
2025
Q4 		$52 Hold
12
– – ﹤0.01% 1416
2025
Q3 		$468 Hold
12
– – ﹤0.01% 1273
2025
Q2 		$280 Buy
+12
New +$284 ﹤0.01% 1233

Other funds holding TVRD

SPC
Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AFG
American Financial Group Cincinnati, Ohio $284M AUM 12.01% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $15.3B AUM 40.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DWAM
Duncan Williams Asset Management Memphis, Tennessee $444M AUM 24.78% 1-Year Est. Return

Leonteq Securities AG's TVRD Position: Q2 2026 in Review

Leonteq Securities AG held its Tvardi Therapeutics (TVRD) position steady in Q2 2026 at 12 shares worth $23. The position accounts for ﹤0.01% of the portfolio, ranked #1263.

Leonteq Securities AG first reported a position in TVRD in Q2 2025 and has held it in 5 quarters since. The position peaked at $468 in Q3 2025. 58 funds tracked by Wall St. Rank hold TVRD as of Q2 2026.

  • Leonteq Securities AG held 12 shares of Tvardi Therapeutics worth $23 as of Q2 2026.
  • Leonteq Securities AG left its Tvardi Therapeutics share count unchanged in Q2 2026.
  • Tvardi Therapeutics made up ﹤0.01% of Leonteq Securities AG's portfolio in Q2 2026, its #1263 holding.
  • Leonteq Securities AG first reported a position in Tvardi Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Leonteq Securities AG's Tvardi Therapeutics position peaked at $468 in Q3 2025.
  • 58 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2026.

Based on Leonteq Securities AG's 13F filing for Q2 2026, filed 27 Jul 2026.